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Primary HIV infection in a Crohn’s disease patient receiving infliximab maintenance therapy
Tumor necrosis factor a (TNFa) plays a complex and
even paradoxical role in the natural history of HIV
infection. Serum levels of this cytokine are elevated
prematurely after the acquisition of the virus and can
exert a protective function, as it was shown to inhibit
HIV-1 entry into primary macrophages in vitro [1].
Conversely, TNFa itself and HIV-1 proteins, which
mimic TNFa signaling, have been reported to activate
nuclear factor kappa B, thus stimulating viral replication
and persistence [2,3]. Furthermore, TNFa-blocking
agents are associated with an increased susceptibility to
infectious complications, underlying the intimate
involvement of this cytokine in the response to
intracellular pathogens [4]. Hence, concerns arose
regarding the use of those drugs in already immunocom-
promised patients, such as HIV-infected ones. Primary
HIV infection during anti-TNFa therapy, which could
influence therapeutic decisions and constitute a chal-
lenge in the management of such patient, was not
addressed before in the literature.
A 16-year-old woman who was diagnosed with colonic
and complex perianal Crohn’s disease started infliximab
(IFX) in 2008 (5 mg/kg, at 0, 2, and 6 weeks, followed by
maintenance infusions every 8 weeks). Screening exams
prior to anti-TNFa initiation, including HIV testing,
were unremarkable. In July 2015, being in clinical
remission for 1 year, she presented with a 24-h history of
a nonpruriginous skin rash and fever, denying any
gastrointestinal symptoms. She recalled unprotected
intercourse during the last few weeks with a partner
who had a recent diagnosis of urethritis. Laboratory
studies demonstrated lymphopenia and a positive p24
antigen, with an undetectable anti-HIV 1/2 antibody.
Further evaluation, performed 2 weeks later, confirmed
HIV-1 seroconversion by Western blot, also showing a
viral load of 74.941 copies/ml (4.87 log) and a CD4þ
T-cell count of 899 cells/ml. After careful consideration of
benefits and risks, it was decided to start HAART with
Emtricitabine/Tenofovir disoproxil fumarate (200 and
245 mg) and Darunavir/ritonavir (800 and 100 mg) and
to maintain IFX maintenance therapy. Currently, with a
follow-up of 18 months, no other complications were
documented. CD4þ T-cell levels remained stable and
above 1.000 cells/ml throughout this period, having
achieved an undetectable viral load (Fig. 1a,b). Regarding
Crohn’s disease, the patient maintained clinical and
endoscopic remission without any IFX-related adverse
events.
In a review of the literature, we identified 29 case reports
of HIV-positive patients who received TNFa antagonists
in the clinical practice [5–7]. Noteworthy, the vast
majority of those study participants (86%) were also under
HAART. In all cases, HIV infection preceded biological
therapy initiation. Infectious complications were reported
in five patients: a diagnosis of pulmonary and nodal
tuberculosis; a facial abscess resolved with antibiotics;
multiple bacterial infections culminating in sepsis and
death; the development of septic shock a few weeks after
influenza vaccination; and the occurrence of a Listeria
monocytogenes meningitis. Remarkably, four of those
five study participants had CD4þ T-cell counts below
500 cells/ml, one of them – the patient who died from
sepsis – having only 20 cells/ml. In a patient like ours,
who had an extensive Crohn’s disease and several
predictive factors for relapse [8], stopping anti-TNFa
treatment could have been deleterious. Additionally, anti-
TNFa monoclonal antibodies induce leukocyte apopto-
sis in the intestinal lamina propria, especially of CD4þ
cells, which is one of the key mechanisms for the
resolution of the inflammatory infiltrate and prevention
of chronicity [4]. Data regarding a possible association
between anti-TNFa therapy and variations in peripheral
CD4þ T-cell counts are conflicting [9–12]. In our case, it
was possible to verify that, after an initial rise, the absolute
levels of CD4þ T cells stabilized above 1000 cells/ml,
denoting small variations between measurements
performed before and following drug’s infusions
(Fig. 1a,b). In fact, in patientswhoexperienced resumption
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Fig. 1. Evolution of CD4R T-cell counts (a) and viral load (b) after IFX initiation. Arrows identify the timing of IFX administration.
IFX, infliximab.
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of HIV replication after HAART discontinuation, an
increase in TNFa circulating levels was observed, which
was shown to correlate with the degree of CD4þ T-cell
decline [13]. Based on the results from this randomized,
controlled trial, we may hypothesize that TNFa blockage
may have contributed to attenuate CD4þ T-cell loss
following HIV infection, allowing themaintenanceof high
cell counts even before HAART initiation.
Taking this into account, one can propose that TNFa
inhibition may be well tolerated in patients who remain
with high CD4þ levels, such as the one we presented.
With this purpose, early HAART should be considered in
study participants with HIV who may require those
agents in a near future. Accordingly, in some HIV patients
with long-term remission of inflammatory bowel disease,
the degree of immunosuppression may play a role in the
decision of maintaining or stopping the treatment. In the
case described, the clinical presentation of primary HIV
infection and the course of the disease were not more
severe despite TNFa suppression. Our report suggests
that maintaining IFX treatment, when HAART is applied
and under close monitoring, may be effective and well
tolerated in patients presenting with acute HIV infection.
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